Relay Therapeutics, Inc. Common Stock (RLAY) is a publicly traded Healthcare sector company. As of May 19, 2026, RLAY trades at $13.14 with a market cap of $2.34B and a P/E ratio of -7.54. RLAY moved +11.53% today. Year to date, RLAY is +47.92%; over the trailing twelve months it is +330.61%. Its 52-week range spans $1.78 to $17.32. Analyst consensus is strong buy with an average price target of $20.78. Rallies surfaces RLAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Relay Therapeutics Shares Jump 15% after 60% Response Rate in Phase 2 Trial: Relay Therapeutics reported Phase 2 ReInspire data showing a 60% 12-week volumetric response and 89% clinical improvement in 20 evaluable PIK3CA-driven vascular anomalies patients, with no discontinuations. At 100mg twice daily, 29% responded and expansion arms at 400mg once daily and 300mg twice daily are now open.
| Metric | Value |
|---|---|
| Price | $13.14 |
| Market Cap | $2.34B |
| P/E Ratio | -7.54 |
| EPS | $-1.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.32 |
| 52-Week Low | $1.78 |
| Volume | 9.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $10.68M |
| Net Income | $-272.70M |
| Gross Margin | 0.00% |
10 analysts cover RLAY: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.78.